AnaptysBio, Gilead partner to develop antibody therapeutics

As a part of the agreement, Gilead will receive antibodies produced by AnaptysBio by the means of SHM-XEL platform, for the development and commercialization.

AnaptysBio president and chief executive officer Hamza Suria said, "Our pharma partners continue to recognize the unique advantages of AnaptysBio’s SHM-XEL antibody generation platform."

AnaptysBio has received upfront fee from Gilead and is yet to receive development milestone payments, royalties upon sales of each product derived from the partnership.

Gilead will carry on providing funds, through the antibody generation process, to AnaptysBio.